启迪药业(000590) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥101,199,883.45, representing a 10.76% increase compared to ¥91,371,093.42 in the same period last year[5] - Net profit attributable to shareholders decreased by 47.33% to ¥6,584,800.39 from ¥12,501,913.58 year-on-year[5] - Basic and diluted earnings per share both fell by 47.32% to ¥0.0275 from ¥0.0522 in the same period last year[5] - In Q1 2023, the company's net profit was CNY 6,608,510.61, a decrease of 46.9% compared to CNY 12,450,763.04 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 8,275,180.58, down 44.1% from CNY 14,824,181.88 in the same period last year[18] - Total revenue from operating activities was CNY 71,177,372.95, a decline of 8.8% compared to CNY 78,919,381.36 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥71,412,078.80, a decline of 87.61% compared to -¥38,063,764.03 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -71,412,078.80, worsening from CNY -38,063,764.03 in the previous year[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 181,835,488.02, compared to CNY 119,572,132.68 at the end of Q1 2022[20] - The company's cash flow from financing activities increased significantly by 1312.92% to ¥18,670,529.41, primarily due to new bank loans[9] - The company’s financing activities generated a net cash inflow of CNY 18,670,529.41, compared to CNY 1,321,413.90 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,160,864,614.18, a decrease of 0.50% from ¥1,166,753,854.92 at the end of the previous year[5] - Total assets as of March 31, 2023, were ¥1,160,864,614.18, down from ¥1,166,753,854.92 at the beginning of the year, a decrease of 0.5%[16] - Total liabilities decreased to ¥451,762,232.36 from ¥464,259,983.71, a decline of 2.7%[16] - The company's equity attributable to shareholders increased by 0.94% to ¥705,053,220.37 from ¥698,468,419.98 at the end of the previous year[5] Expenses - Total operating costs for Q1 2023 were ¥94,851,970.71, up 21.2% from ¥78,324,425.75 in Q1 2022[17] - The company recorded a net loss from operating activities, with a significant increase in expenses leading to a net profit decline of 46.92%[9] - Research and development expenses increased to CNY 3,035,083.94, up from CNY 2,678,282.04 in the previous year, reflecting a focus on innovation[18] - The company recorded a significant decrease in sales expenses, which rose to CNY 22,923,928.51 from CNY 15,070,557.79, indicating increased investment in marketing[18] - The company's financial expenses included interest expenses of CNY 1,051,034.62, compared to CNY 96,635.60 in the previous year, highlighting increased borrowing costs[18] Receivables and Inventory - The company's receivables financing increased by 60.89% to ¥86,750,573.95, mainly due to an increase in received bills[8] - The company reported a significant increase in accounts receivable financing to ¥86,750,573.95 from ¥53,920,546.58, an increase of 60.9%[15] - Accounts receivable decreased to ¥18,867,109.01 from ¥24,369,559.97, a reduction of 22.6%[15] - Inventory increased to ¥133,364,483.70 from ¥118,222,841.95, reflecting a growth of 12.8%[15] Shareholder Information - The number of major shareholders includes启迪科技服务有限公司 with 70,432,904 shares, representing a significant portion of the company's equity[12]